世界中医药
文章摘要
引用本文:赵君1,2,章轶立1,谢雁鸣1,陈仁波1,盖国忠1.真实世界脉血康胶囊治疗乳房肿瘤的联合用药特征[J].世界中医药,2021,(15):.  
真实世界脉血康胶囊治疗乳房肿瘤的联合用药特征
Study on Clinical Application Characteristics of Maixuekang Capsules in Combination with Modern Medicine in Treating Breast Tumors in the Real World
投稿时间:2019-11-04  
DOI:10.3969/j.issn.1673-7202.2021.15.024
中文关键词:  真实世界  脉血康胶囊  乳房肿瘤  联合用药  药理作用  抗肿瘤药  关联规则  频数
English Keywords:Real world  Maixuekang Capsules  Breast tumors  Combination medications  Pharmacological effects  Antitumor drugs  Association rules  Frequency
基金项目:中央级公益性科研院所基本业务费项目(Z0439);中国中医科学院科技创新团队(PY1303)
作者单位
赵君1,2,章轶立1,谢雁鸣1,陈仁波1,盖国忠1 1 中国中医科学院中医临床基础医学研究所北京100700 2 中国中医科学院针灸研究所北京100700 
摘要点击次数: 242
全文下载次数: 0
中文摘要:
      目的:分析真实世界脉血康胶囊治疗乳房肿瘤的联合用药特征,探索其潜在治疗方法,以期为临床合理用药提供参考和借鉴。方法:采用频数统计和关联规则对全国7家大型三级甲等综合医院信息系统数据库中使用脉血康胶囊治疗乳房肿瘤的416例患者的临床用药信息进行分析。结果:使用脉血康胶囊治疗乳房肿瘤的患者,女性多于男性;年龄主要分布在18~44岁,呈现年轻化趋势;平均疗程(663±556)d;西药类的抗病毒药、抗生素类、促凝血药、血管活性药、抗肿瘤辅助药及中药中的消肿散结剂等常与脉血康胶囊联用;出院时总转归判定的有效率为5024%。结论:基于目前数据发现,脉血康胶囊治疗乳房肿瘤人群具有一定的人群特点和临床用药特征,在一定程度上可为脉血康胶囊合理治疗乳房肿瘤患者提供参考证据与借鉴。
English Summary:
      To analyze the clinic application of Maixuekang Capsules in the treatment of breast tumors in the real world and explore its potential therapeutic methods, in order to improve the clinical rational drug use and provide reference. Methods:Frequency statistics and association rules were used to analyze the clinical drug use information of Maixuekang Capsule for treating 416 breast tumor patients in the database of hospital information system from 7 Grade 3A general hospital information system. Results:Among the patients treated with Maixuekang Capsules, women were more than men. The age was mainly distributed between 18 and 44 years old, showing a younger trend. The average course of treatment was (6.63±5.56) days. Maixuekang Capsule was often used in combination with antiviral drugs, antibiotics, procoagulant, vasoactive agents and antitumor adjuvant in Western medicine, as well as Chinese medicine with the function of softening hard lumps and dispelling nodes. The effective rate of total return at discharge was 50.24%. Conclusion:Based on the current data, it is found that Maixuekang Capsules has certain characteristics of the population and clear clinical characteristics and to a certain extent, the study can provide reference evidence and reference for the rational treatment of breast cancer patients with Maixuekang Capsule.
查看全文  查看/发表评论  下载PDF阅读器